A phase III clinical trial demonstrated that a combination of anti-VEGF monoclonal antibody bevacizumab with carboplatin–paclitaxel significantly improved overall survival (OS) in lung cancer patients compared to chemotherapy alone [36]. This evidence concerns the gene VEGFA and lung carcinoma.